Developer docs
API playgroundTry for free, no card

Search company profiles

Syqe Medical

Full company profile

uuid0002arw

Namestring
Syqe Medical
Legal namestring
Syqe Medical Ltd.
Websiteurl
syqe.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Syqe Medical Ltd. is an Israeli med-tech company founded in 2011 that has developed the SyqeAir platform, the world's first metered-dose medical cannabis inhaler. The system combines a proprietary electromechanical inhaler (featuring Electronic Selective-Dose™, ActiveFlow™, and PulseBreath™ mechanisms) with single-use SyqeAir Cartridges containing 60 standardized doses of full-spectrum Bedrocan cannabis, and a companion mobile app for treatment management. The technology delivers precise 250–1,000 microgram THC doses per inhalation, which the company reports results in 79x lower daily THC exposure, 90% fewer adverse effects, and 92% of patients reporting quality-of-life improvement in real-world evidence from over 1,249 patients.

Syqe generates revenue through hardware (inhaler device) and recurring cartridge sales distributed via exclusive pharmaceutical partners — Teva in Israel and Novachem in Australia — supplemented by direct pharmacy and app-based reordering. The company has obtained regulatory approvals in Israel (AMAR/MDL/CE), Canada (Health Canada, 2021), and Australia (TGA, 2023), and became the first Israeli company to receive EU-GMP certification for a cannabis inhalation product in January 2024. The company targets multiple patient segments, with chronic neuropathic pain as the primary indication (53% of Israel's 123,714 medical cannabis licensees), and has secured government-backed veteran access programs in both Israel (Ministry of Defense, 2023) and Australia (DVA, 2025). The company has raised $83 million cumulatively through investors including Shavit Capital and Philip Morris International, holds over 160 patents, and is currently expanding into European markets including Germany, the UK, and Denmark.

Short descriptiontext

Syqe Medical is an Israeli med-tech company that has developed the SyqeAir, the world's first metered-dose medical cannabis inhaler, serving chronic pain, PTSD, oncology, and veteran patients across Israel, Australia, Canada, and select EU markets with pharmaceutical-grade precision dosing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
metered-dose inhalers, medical cannabis devices, pharmaceutical inhalation systems, cannabis drug delivery, precision dose inhalers
Industry1 code
PRIMARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Cannabis Inhalation Devices
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1SyqeAir Inhaler Device Sales
TypeHardware Sales
Description

Sale of the SyqeAir medical inhaler device - a hardware product that enables precise metered-dose medical cannabis administration.

syqe.com
2SyqeAir Cartridge Sales
TypeHardware Sales
Description

Recurring sales of proprietary cartridges containing 60 metered doses each. Each cartridge uses Bedrocan® standardized cannabis. Cartridges can be ordered directly from pharmacies through the SyqeAir App.

syqe.com
3Clinical Trial Services
TypeProfessional Services
Description

Syqe Medical serves as international sponsor for clinical trials, operating under fee-for-service arrangements with CROs. The company conducts clinical trials to demonstrate effectiveness and safety of the SyqeAir inhaler.

westernsydney.edu.au
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1SyqeAir Inhaler and Cartridge system - prescription medical device
ModelOtherBilling cadencePay-as-you-go
Notes

Quote-based pricing through pharmacies with medical prescription. Government subsidies available in Australia for eligible veterans through TGA/DVA program.

westernsydney.edu.au
2SyqeAir Cartridge refill (60 metered doses)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Cartridges available for reorder through pharmacies and directly via the SyqeAir App.

syqe.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1SyqeAir
Description

The flagship product - a metered-dose medical cannabis inhaler that delivers precise, consistent, and low doses of THC for treatment of chronic neuropathic pain with minimal psychoactive effects.

syqe.com
+2 more records
Core offering1 text field

Syqe Medical manufactures and sells the SyqeAir system, a prescription-only metered-dose medical cannabis inhaler platform. The system consists of the SyqeAir Inhaler device, proprietary SyqeAir Cartridges (each containing 60 pre-measured doses of standardized Bedrocan cannabis), the SyqeAir companion mobile app, and a nurse-guided Patient Support Program for personalized dosing. It delivers precise THC doses (250-1000 mcg) for chronic neuropathic pain, PTSD, and oncology symptom management with minimal psychoactive effects.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 92% of patients report quality of life improvement
+6 more records
Product overview1 text field

Syqe Medical is a MedTech company offering the SyqeAir system — a comprehensive medical cannabis treatment platform comprising the SyqeAir Metered-Dose Inhaler (the world's first metered-dose cannabis inhaler), proprietary SyqeAir Cartridges containing 60 doses of Bedrocan standardized cannabis, the SyqeAir companion mobile app, and nursing-guided Patient Support Program. The system applies pharmaceutical-grade principles to medical cannabis delivery, enabling precise dosing (250-1000 mcg THC), consistent therapeutic effects, and reduced psychoactive side effects compared to traditional routes of administration. The company holds EU-GMP certification and regulatory approvals in Israel, Australia, and Canada.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-15
Description

First-of-its-kind agreement to supply SyqeAir Inhaler and Cartridges to all veterans prescribed medical cannabis. Government partnership enabling veteran access to precise dosing medical cannabis treatment.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2016-01-01
Description

Exclusive marketing and distribution agreement signed in 2016 for the Israeli market. Teva markets SyqeAir inhalers exclusively in Israel, leveraging their established pharmaceutical distribution network and relationships with healthcare providers.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive Israeli importer of Bedrocan® pharmaceutical-grade medicinal cannabis. Bedrocan provides standardized cannabis with reproducible composition from batch to batch, grown under EU-GMP conditions. This partnership ensures consistent therapeutic effect and supply chain quality.

4Novachem
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Australian distributor providing metered-dosing inhaler to patients following TGA approval. Novachem handles distribution logistics and regulatory compliance for the Australian market.

syqe.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Australian CRO (Contract Research Organization) engaged for clinical trial operations. Syneos operates under fee-for-service arrangements for international sponsor Syqe Medical's clinical trials.

6NICM Health Research (Western Sydney University)
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Participant-recruitment site for international clinical trial investigating medicinal cannabis for diabetic peripheral neuropathy. Operating under fee-for-service arrangement with Syneos.

westernsydney.edu.au
7Australian Department of Veterans' Affairs (DVA)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Government funding scheme enabling eligible Australian veterans to access SyqeAir treatment at no cost following TGA approval. DVA subsidies cover device and cartridge costs for approved veterans.

syqe.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Israeli pharmaceutical-grade medical cannabis manufacturer producing standardized dosage formats. Directly comparable to Syqe as a domestic Israeli competitor pursuing pharma-grade cannabis products with EU-GMP ambitions.

TypeDirect peer
Description

Danish-listed medical cannabis company focused on prescription-grade cannabinoid products in European markets. Comparable to Syqe's regulated, pharmaceutical-grade positioning and EU expansion strategy.

TypeDirect peer
Description

German pharmaceutical-grade medical cannabis supplier with EU-GMP certification and a focus on pharmacy-channel distribution. Comparable business model centered on pharma-grade cannabis in regulated European markets.

TypeOthers
Description

Dutch producer of standardized pharmaceutical-grade cannabis and Syqe's exclusive cannabis supplier. Comparable due to its standardized, batch-reproducible cannabis positioning and EU-GMP cultivation.

TypeBroad incumbent
Description

Acquired GW Pharmaceuticals and Epidiolex, becoming a leading pharmaceutical company with FDA-approved cannabinoid medicines. Comparable as a large incumbent bringing prescription-grade cannabis products to global markets.

6Tilray Brands
TypeBroad incumbent
Description

Global cannabis company with a medical cannabis division across multiple countries. Comparable as a broad incumbent offering medical cannabis products in markets where Syqe also operates or targets.

TypeOthers
Description

Philip Morris International subsidiary focused on inhalation drug delivery technology and a historical investor/partner of Syqe. Comparable as a strategic peer in metered-dose inhalation technology and a connected party in Syqe's cap table.

TypeBroad incumbent
Description

Large multi-jurisdiction cannabis operator with a Spectrum Therapeutics medical cannabis portfolio. Comparable as a broad incumbent competing in medical cannabis markets where Syqe is approved or expanding.

TypeBroad incumbent
Description

Major medical cannabis producers with operations in Canada, Australia, and Europe. Comparable as incumbents in the same regulated geographies Syqe has secured approvals in.

TypeBroad incumbent
Description

Global pharmaceutical company with deep expertise in metered-dose inhalers (MDI/DPI) for respiratory conditions. Comparable on the drug delivery inhaler technology axis, with potential adjacent applicability to cannabis delivery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Syqe Medical

Medical Cannabis Inhalation Devicessyqe.com

Syqe Medical is an Israeli med-tech company that has developed the SyqeAir, the world's first metered-dose medical cannabis inhaler, serving chronic pain, PTSD, oncology, and veteran patients across Israel, Australia, Canada, and select EU markets with pharmaceutical-grade precision dosing.

What Syqe Medical does

Syqe Medical Ltd. is an Israeli med-tech company founded in 2011 that has developed the SyqeAir platform, the world's first metered-dose medical cannabis inhaler. The system combines a proprietary electromechanical inhaler (featuring Electronic Selective-Dose™, ActiveFlow™, and PulseBreath™ mechanisms) with single-use SyqeAir Cartridges containing 60 standardized doses of full-spectrum Bedrocan cannabis, and a companion mobile app for treatment management. The technology delivers precise 250–1,000 microgram THC doses per inhalation, which the company reports results in 79x lower daily THC exposure, 90% fewer adverse effects, and 92% of patients reporting quality-of-life improvement in real-world evidence from over 1,249 patients.

Syqe generates revenue through hardware (inhaler device) and recurring cartridge sales distributed via exclusive pharmaceutical partners — Teva in Israel and Novachem in Australia — supplemented by direct pharmacy and app-based reordering. The company has obtained regulatory approvals in Israel (AMAR/MDL/CE), Canada (Health Canada, 2021), and Australia (TGA, 2023), and became the first Israeli company to receive EU-GMP certification for a cannabis inhalation product in January 2024. The company targets multiple patient segments, with chronic neuropathic pain as the primary indication (53% of Israel's 123,714 medical cannabis licensees), and has secured government-backed veteran access programs in both Israel (Ministry of Defense, 2023) and Australia (DVA, 2025). The company has raised $83 million cumulatively through investors including Shavit Capital and Philip Morris International, holds over 160 patents, and is currently expanding into European markets including Germany, the UK, and Denmark.

Syqe Medical firmographics

Firmographics
Name
Syqe Medical
Legal name
Syqe Medical Ltd.
Website
https://syqe.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
Syqe Medical is an Israeli med-tech company that has developed the SyqeAir, the world's first metered-dose medical cannabis inhaler, serving chronic pain, PTSD, oncology, and veteran patients across Israel, Australia, Canada, and select EU markets with pharmaceutical-grade precision dosing.
Ownership category
akta.pro rank

Syqe Medical industry classification

Industry
Product category
Medical Cannabis Inhalation Devices
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Metered-dose inhalers
  • Medical cannabis devices
  • Pharmaceutical inhalation systems
  • Cannabis drug delivery
  • Precision dose inhalers

Where Syqe Medical is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Syqe Medical business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. SyqeAir Inhaler Device Sales: Sale of the SyqeAir medical inhaler device - a hardware product that enables precise metered-dose medical cannabis administration.
  2. SyqeAir Cartridge Sales: Recurring sales of proprietary cartridges containing 60 metered doses each. Each cartridge uses Bedrocan® standardized cannabis. Cartridges can be ordered directly from pharmacies through the SyqeAir App.
  3. Clinical Trial Services: Syqe Medical serves as international sponsor for clinical trials, operating under fee-for-service arrangements with CROs. The company conducts clinical trials to demonstrate effectiveness and safety of the SyqeAir inhaler.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goSyqeAir Inhaler and Cartridge system - prescription medical device
Unit PricingPay-as-you-goSyqeAir Cartridge refill (60 metered doses)

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Syqe Medical product offering

Product offering

Core offering

Syqe Medical manufactures and sells the SyqeAir system, a prescription-only metered-dose medical cannabis inhaler platform. The system consists of the SyqeAir Inhaler device, proprietary SyqeAir Cartridges (each containing 60 pre-measured doses of standardized Bedrocan cannabis), the SyqeAir companion mobile app, and a nurse-guided Patient Support Program for personalized dosing. It delivers precise THC doses (250-1000 mcg) for chronic neuropathic pain, PTSD, and oncology symptom management with minimal psychoactive effects.

Product overview

Syqe Medical is a MedTech company offering the SyqeAir system — a comprehensive medical cannabis treatment platform comprising the SyqeAir Metered-Dose Inhaler (the world's first metered-dose cannabis inhaler), proprietary SyqeAir Cartridges containing 60 doses of Bedrocan standardized cannabis, the SyqeAir companion mobile app, and nursing-guided Patient Support Program. The system applies pharmaceutical-grade principles to medical cannabis delivery, enabling precise dosing (250-1000 mcg THC), consistent therapeutic effects, and reduced psychoactive side effects compared to traditional routes of administration. The company holds EU-GMP certification and regulatory approvals in Israel, Australia, and Canada.

Differentiator

Problem solved

Functional benefit

Brands

  • SyqeAir: The flagship product - a metered-dose medical cannabis inhaler that delivers precise, consistent, and low doses of THC for treatment of chronic neuropathic pain with minimal psychoactive effects.
  • SyqeAir Cartridge
  • SyqeAir App

Quantifiable outcome

  • 92% of patients report quality of life improvement
  • +6 more outcomes

Companies that use Syqe Medical

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Syqe Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature7 records

Syqe Medical partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, regional and minor.

  • Israeli Ministry of DefensecoreStrategic or Co-development Partner · 15 February 2023First-of-its-kind agreement to supply SyqeAir Inhaler and Cartridges to all veterans prescribed medical cannabis. Government partnership enabling veteran access to precise dosing medical cannabis treatment.
  • Teva PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 January 2016Exclusive marketing and distribution agreement signed in 2016 for the Israeli market. Teva markets SyqeAir inhalers exclusively in Israel, leveraging their established pharmaceutical distribution network and relationships with healthcare providers.
  • BedrocancoreStrategic or Co-development PartnerExclusive Israeli importer of Bedrocan® pharmaceutical-grade medicinal cannabis. Bedrocan provides standardized cannabis with reproducible composition from batch to batch, grown under EU-GMP conditions. This partnership ensures consistent therapeutic effect and supply chain quality.
  • NovachemregionalChannel Partner/ Reseller/ DistributorAustralian distributor providing metered-dosing inhaler to patients following TGA approval. Novachem handles distribution logistics and regulatory compliance for the Australian market.
  • Syneos HealthminorImplementation/ SI/ Consulting PartnerAustralian CRO (Contract Research Organization) engaged for clinical trial operations. Syneos operates under fee-for-service arrangements for international sponsor Syqe Medical's clinical trials.
  • NICM Health Research (Western Sydney University)minorImplementation/ SI/ Consulting PartnerParticipant-recruitment site for international clinical trial investigating medicinal cannabis for diabetic peripheral neuropathy. Operating under fee-for-service arrangement with Syneos.
  • Australian Department of Veterans' Affairs (DVA)regionalChannel Partner/ Reseller/ DistributorGovernment funding scheme enabling eligible Australian veterans to access SyqeAir treatment at no cost following TGA approval. DVA subsidies cover device and cartridge costs for approved veterans.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Syqe Medical competitors and assessment

Company assessment

Direct peers

  • Panaxia Pharmaceutical Industries: Israeli pharmaceutical-grade medical cannabis manufacturer producing standardized dosage formats. Directly comparable to Syqe as a domestic Israeli competitor pursuing pharma-grade cannabis products with EU-GMP ambitions.
  • STENOCARE: Danish-listed medical cannabis company focused on prescription-grade cannabinoid products in European markets. Comparable to Syqe's regulated, pharmaceutical-grade positioning and EU expansion strategy.
  • Cannamedical Pharma: German pharmaceutical-grade medical cannabis supplier with EU-GMP certification and a focus on pharmacy-channel distribution. Comparable business model centered on pharma-grade cannabis in regulated European markets.

Others

  • Bedrocan: Dutch producer of standardized pharmaceutical-grade cannabis and Syqe's exclusive cannabis supplier. Comparable due to its standardized, batch-reproducible cannabis positioning and EU-GMP cultivation.
  • Vectura Fertin Pharma: Philip Morris International subsidiary focused on inhalation drug delivery technology and a historical investor/partner of Syqe. Comparable as a strategic peer in metered-dose inhalation technology and a connected party in Syqe's cap table.

Broad incumbents

  • Jazz Pharmaceuticals: Acquired GW Pharmaceuticals and Epidiolex, becoming a leading pharmaceutical company with FDA-approved cannabinoid medicines. Comparable as a large incumbent bringing prescription-grade cannabis products to global markets.
  • Tilray Brands: Global cannabis company with a medical cannabis division across multiple countries. Comparable as a broad incumbent offering medical cannabis products in markets where Syqe also operates or targets.
  • Canopy Growth: Large multi-jurisdiction cannabis operator with a Spectrum Therapeutics medical cannabis portfolio. Comparable as a broad incumbent competing in medical cannabis markets where Syqe is approved or expanding.
  • Aphria / Aurora Cannabis: Major medical cannabis producers with operations in Canada, Australia, and Europe. Comparable as incumbents in the same regulated geographies Syqe has secured approvals in.
  • Cipla: Global pharmaceutical company with deep expertise in metered-dose inhalers (MDI/DPI) for respiratory conditions. Comparable on the drug delivery inhaler technology axis, with potential adjacent applicability to cannabis delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Syqe Medical social profiles

Digital presence

Syqe Medical compliance and trust

Trust signal

Compliance6 records

Syqe Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Syqe Medical leadership team

Management profile

Number of profiles

Profiles2 records

Syqe Medical funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Syqe Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syqe Medical

What does Syqe Medical do?

Syqe Medical manufactures and sells the SyqeAir system, a prescription-only metered-dose medical cannabis inhaler platform. The system consists of the SyqeAir Inhaler device, proprietary SyqeAir Cartridges (each containing 60 pre-measured doses of standardized Bedrocan cannabis), the SyqeAir companion mobile app, and a nurse-guided Patient Support Program for personalized dosing. It delivers precise THC doses (250-1000 mcg) for chronic neuropathic pain, PTSD, and oncology symptom management with minimal psychoactive effects.

Is Syqe Medical a public or private company?

Syqe Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Syqe Medical founded?

Syqe Medical was founded in 2011. It employs 51 to 100 people.

Where is Syqe Medical based?

Syqe Medical is headquartered in Tel Aviv, Israel, in the Middle East region.

How does Syqe Medical make money?

Three revenue lines are on record. SyqeAir Inhaler Device Sales are the primary driver. The others are syqeAir Cartridge Sales and clinical Trial Services.

Who are Syqe Medical's main competitors?

Direct peers on record are Panaxia Pharmaceutical Industries, STENOCARE and Cannamedical Pharma. Others are Bedrocan and Vectura Fertin Pharma. Broad incumbents are Jazz Pharmaceuticals, Tilray Brands, Canopy Growth, Aphria / Aurora Cannabis and Cipla.

Does Syqe Medical have an API?

No public API is recorded for Syqe Medical.

What industry is Syqe Medical in?

Syqe Medical's product category is Medical Cannabis Inhalation Devices. Its primary akta.pro industry code is HLAHAIAI, Inhalers (MDI/DPI/SMI). Its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Western Sydney UniversityStatement: NICM Health Research’s participation in global trial on Diabetic Peripheral NeuropathyWestern Sydney University's NICM Health Research has issued a statement clarifying its limited role as a participant-recruitment site in an international clinical trial investigating medicinal cannabis for diabetic peripheral neuropathy. NICM is operating under a fee-for-service arrangement with Australian CRO Syneos and notes that Israeli-based Syqe Medical serves as the trial's international sponsor, having received historical funding from Philip Morris International subsidiary Vectura Fertin Pharma. The statement emphasizes the trial's potential to address a condition affecting approximately half of Australia's 1.5 million people with diabetes, while NICM maintains it has no involvement in the broader study's development or oversight.YahooTop 20 Countries With The Highest Weed ConsumptionThe article lists the top 20 countries with highest weed consumption, noting 70 countries have legalized cannabis in some form. The global cannabis market was valued at $43.72 billion in 2022 and is projected to reach $444.34 billion by 2030. It also cites a deal between Phillip Morris and Syqe Medical as a step toward growth.Yahoo26 Biggest Marijuana Companies in the WorldThe article ranks 26 cannabis companies by market cap, with Syqe Medical at $650 million and Cronos Group at $704.5 million. The global cannabis market is projected to grow from $43.72 billion in 2022 to $444.34 billion by 2030. Philip Morris International is attempting to acquire Syqe Medical for $650 million.ForbesPhilip Morris To Acquire Israeli Cannabis Inhaler Company Syqe Medical For Up To $650 MillionPhilip Morris plans to acquire Israeli cannabis inhaler company Syqe Medical for up to $650 million, investing $120 million initially to secure FDA approval. The deal would make Syqe one of the top ten cannabis companies globally. The inhaler uses raw cannabis inflorescence and is currently available in Israel and Australia.MjbizdailyPhilip Morris buying Israeli cannabis firm for up to $650M, report saysPhilip Morris International is reportedly acquiring Israeli cannabis technology firm Syqe Medical in a deal valued at up to $650 million, contingent on regulatory approvals. The transaction includes an initial $120 million investment, with the remainder tied to obtaining U.S. Food and Drug Administration approval for Syqe's medical cannabis inhaler. This move positions Philip Morris to enter the vaped medical cannabis market, which analysts project could be worth $22 billion over the next decade.PR NewswireSyqe Medical Announces Agreement with Israeli Ministry of Defence to Provide the SyqeAir Technology to VeteransSyqe Medical signed an agreement with the Israeli Ministry of Defence to supply the SyqeAir Inhaler and Cartridges to veterans prescribed medical cannabis, making it the first agreement of its kind to position medical cannabis through inhalation as a standard treatment option alongside pharmaceutical drugs. The SyqeAir device is a metered-dose inhaler that delivers precise, consistent doses of pharmaceutical-grade cannabis grown by Dutch company Bedrocan, and is CE and Health Canada approved with clinical validation from three trials. The partnership is intended to serve veterans suffering from chronic pain and PTSD, with company executives expressing hope it will become a model for other countries.ForbesWhy Cannabis Is Part Of The Future Of Big TobaccoBig Tobacco companies are diversifying into the cannabis industry, with BAT launching its first CBD vaping product VUSE CBD Zone in 2021. Investments include PMI's $20 million in Syqe Medical and Altria's $1.8 billion stake in Cronos Group. The shift reflects a move toward less harmful alternatives and medical cannabis.PR NewswireSyqe Medical Named to Fast Company's Annual List of the World's Most Innovative Companies for 2020Syqe Medical, an Israeli pharma-tech company, has been ranked in Fast Company's top 10 biotech companies in the 2020 Most Innovative Companies List, which honors businesses making significant impact across 434 organizations from 39 countries. The company's flagship product, the Syqe Inhaler™, is the world's first programmable pulmonary drug delivery platform capable of administering metered doses of plants and pharmaceuticals at therapeutic standards, with clinical data showing patients using up to 90 percent less medical cannabis compared to smoking or vaporizing. The technology, currently marketed by Teva Pharmaceuticals in Israel following approval from the Israeli Ministry of Health, enables precise dosage control and remote clinical monitoring for conditions including pain, CNS disorders, and anxiety.PR NewswireSyqe Enters Into Distribution Agreement With TerrAscend to Bring Revolutionary Medical Cannabis Treatment to CanadaSyqe Medical, Ltd. and TerrAscend Corp. announced an exclusive distribution agreement to bring the Syqe Inhaler, a metered-dose medical cannabis device, to the Canadian market. TerrAscend will lead marketing, distribution, and sales efforts across Canada using its Solace Health Network platform. This partnership aims to provide precise, pharmaceutical-standard dosing for medical cannabis patients, addressing deficiencies in current delivery methods.GlobesCannabis inhaler co Syqe seeks Toronto IPOSyqe Medical, an Israeli cannabis inhaler developer, plans a Toronto Stock Exchange IPO by year-end at a valuation of hundreds of millions of dollars. The company raised $50 million last year, its largest financing round, and Teva has marketed its products since June. It aims to expand inhalers for other herbal and conventional drugs.